These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 1346673)

  • 1. Adjuvant treatment in breast cancer.
    Powles TJ; Smith IE
    Lancet; 1992 Feb; 339(8790):423. PubMed ID: 1346673
    [No Abstract]   [Full Text] [Related]  

  • 2. Is adjuvant chemotherapy useful for women with luminal a breast cancer?
    Coates AS; Colleoni M; Goldhirsch A
    J Clin Oncol; 2012 Apr; 30(12):1260-3. PubMed ID: 22355052
    [No Abstract]   [Full Text] [Related]  

  • 3. Twelve-year mortality results of a randomized trial of 2 versus 5 years of adjuvant tamoxifen for postmenopausal early-stage breast carcinoma patients (SITAM 01).
    Alliot C
    Cancer; 2006 Jul; 107(1):215; author reply 215-6. PubMed ID: 16691577
    [No Abstract]   [Full Text] [Related]  

  • 4. [What is the benefit of adjuvant therapy in breast cancer?].
    Sauer H
    Fortschr Med; 1992 Nov; 110(30):16-8, 20. PubMed ID: 1468737
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of tamoxifen as treatment of breast cancer.
    Powles TJ
    Semin Oncol; 1997 Feb; 24(1 Suppl 1):S1-48-S1-54. PubMed ID: 9045315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
    Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aromatase inhibitors as adjuvant therapy for breast cancer: overall survival versus disease-free survival as a primary end point in clinical practice.
    Sánchez-Muñoz A; Ribelles N; Márquez A; Pérez-Ruiz E; Alba E
    J Clin Oncol; 2009 Dec; 27(35):e255-6; author reply e257-8. PubMed ID: 19884520
    [No Abstract]   [Full Text] [Related]  

  • 8. Adjuvant treatment of breast cancer.
    Akerley WL
    R I Med; 1995 Sep; 78(9):250-3. PubMed ID: 7579720
    [No Abstract]   [Full Text] [Related]  

  • 9. Strength of ER-positivity in relation to survival in ER-positive breast cancer treated by adjuvant tamoxifen as sole systemic therapy.
    Morgan DA; Refalo NA; Cheung KL
    Breast; 2011 Jun; 20(3):215-9. PubMed ID: 21159509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
    Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
    Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy.
    Filipits M; Rudas M; Heinzl H; Jakesz R; Kubista E; Lax S; Schippinger W; Dietze O; Greil R; Stiglbauer W; Kwasny W; Nader A; Stierer M; Gnant MF;
    Clin Cancer Res; 2009 Sep; 15(18):5888-94. PubMed ID: 19723645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant tamoxifen and chemotherapy prolongs life and increases disease-free survival of women with breast cancer.
    Oncology (Williston Park); 1992 Jan; 6(1):86. PubMed ID: 1531606
    [No Abstract]   [Full Text] [Related]  

  • 13. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
    Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
    Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.
    Kaufmann M; Graf E; Jonat W; Eiermann W; Geberth M; Albert US; Gademann G; Conrad B; Stahl K; von Minckwitz G; Schumacher M;
    J Clin Oncol; 2005 Nov; 23(31):7842-8. PubMed ID: 16258087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Postoperative hormone therapy of breast cancer (analysis of overall survival)].
    Semiglazov VF; Ivanov VG; Ivanova OA; Moiseenko VM; Tsyrlina EV; Barash NI; Popova RT; Migmanova NS; Seleznev IK; Bozhok AA
    Vopr Onkol; 1996; 42(6):37-42. PubMed ID: 9123900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Tamoxifen adjuvant delays early breast cancer. Results of a cooperative randomized trial].
    Delozier T; Switsers O; Génot JY; Ollivier JM; Héry M; Namer M; Frenay M; Kerbrat P; Julien JP; Naja A; Janvier M; Macé-Lesec'h J
    Bull Cancer; 1997 Jan; 84(1):25-30. PubMed ID: 9180855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
    Mariotto AB; Feuer EJ; Harlan LC; Abrams J
    J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.
    Bernhard J; Luo W; Ribi K; Colleoni M; Burstein HJ; Tondini C; Pinotti G; Spazzapan S; Ruhstaller T; Puglisi F; Pavesi L; Parmar V; Regan MM; Pagani O; Fleming GF; Francis PA; Price KN; Coates AS; Gelber RD; Goldhirsch A; Walley BA
    Lancet Oncol; 2015 Jul; 16(7):848-58. PubMed ID: 26092816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Adjuvant hormonotherapy in cancer of the breast in Oxford meta-analysis. A ten-year experience on more than 30,000 women].
    Bonneterre J
    Pathol Biol (Paris); 1993 Feb; 41(2):135-6. PubMed ID: 8327264
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.